JPWO2020145227A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020145227A5
JPWO2020145227A5 JP2020565732A JP2020565732A JPWO2020145227A5 JP WO2020145227 A5 JPWO2020145227 A5 JP WO2020145227A5 JP 2020565732 A JP2020565732 A JP 2020565732A JP 2020565732 A JP2020565732 A JP 2020565732A JP WO2020145227 A5 JPWO2020145227 A5 JP WO2020145227A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565732A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020145227A1 (ja
JP7414370B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/000036 external-priority patent/WO2020145227A1/ja
Publication of JPWO2020145227A1 publication Critical patent/JPWO2020145227A1/ja
Publication of JPWO2020145227A5 publication Critical patent/JPWO2020145227A5/ja
Application granted granted Critical
Publication of JP7414370B2 publication Critical patent/JP7414370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565732A 2019-01-07 2020-01-06 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体 Active JP7414370B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019000530 2019-01-07
JP2019000530 2019-01-07
JP2019206560 2019-11-14
JP2019206560 2019-11-14
PCT/JP2020/000036 WO2020145227A1 (ja) 2019-01-07 2020-01-06 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体

Publications (3)

Publication Number Publication Date
JPWO2020145227A1 JPWO2020145227A1 (ja) 2021-11-11
JPWO2020145227A5 true JPWO2020145227A5 (https=) 2022-10-24
JP7414370B2 JP7414370B2 (ja) 2024-01-16

Family

ID=71520276

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565732A Active JP7414370B2 (ja) 2019-01-07 2020-01-06 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体
JP2020565733A Pending JPWO2020145228A1 (ja) 2019-01-07 2020-01-06 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020565733A Pending JPWO2020145228A1 (ja) 2019-01-07 2020-01-06 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体

Country Status (17)

Country Link
US (2) US20220105194A1 (https=)
EP (2) EP3909606A4 (https=)
JP (2) JP7414370B2 (https=)
KR (2) KR20210113202A (https=)
CN (2) CN113301920B (https=)
AU (2) AU2020205851B2 (https=)
BR (2) BR112021013361A2 (https=)
CA (2) CA3125745A1 (https=)
CO (2) CO2021010115A2 (https=)
IL (2) IL284623B2 (https=)
JO (2) JOP20210180A1 (https=)
MX (2) MX2021008230A (https=)
PH (2) PH12021551631A1 (https=)
SG (2) SG11202107400QA (https=)
TW (2) TWI850308B (https=)
WO (2) WO2020145227A1 (https=)
ZA (2) ZA202105151B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
AU2021230210A1 (en) 2020-03-04 2022-09-22 Kyoto University Compound and radioactive labeling compound
AU2022228911A1 (en) 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
CN118852043A (zh) * 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
EP4577526A1 (en) * 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Vhh antibody conjugates
CN120957761A (zh) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
WO2024243315A2 (en) * 2023-05-22 2024-11-28 Actinium Pharmaceuticals, Inc. Multi-arm bifunctional chelators
WO2025232118A1 (zh) * 2024-05-10 2025-11-13 四川科伦博泰生物医药股份有限公司 稠环类化合物及其制备方法和用途
WO2026024644A1 (en) 2024-07-23 2026-01-29 Abdera Therapeutics Inc. 5t4 binding polypeptides and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
AU2007304590A1 (en) 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
CN102264765B (zh) 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
US20160095939A1 (en) * 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
WO2011005322A2 (en) * 2009-07-08 2011-01-13 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
AU2010326004B2 (en) * 2009-12-04 2016-04-21 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
EP2471557A1 (en) * 2010-12-27 2012-07-04 Università degli Studi di Genova A conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid useful for the localization of radionuclides for diagnostic and therapeutic purposes
CN114634572A (zh) * 2011-10-10 2022-06-17 希望之城公司 中间位和中间位结合抗体及其用途
JP6164556B2 (ja) 2011-12-01 2017-07-19 国立大学法人 千葉大学 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
JP6847388B2 (ja) * 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
WO2016111797A1 (en) * 2015-01-09 2016-07-14 Immunomedics, Inc. Radiosensitivity of fluorophores and use of radioprotective agents for dual-modality imaging
CN108699108B (zh) * 2016-03-01 2022-04-08 国立大学法人千叶大学 放射性标记药物
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
US10758632B2 (en) * 2017-02-06 2020-09-01 City Of Hope NIR-conjugated tumor-specific antibodies and uses thereof
US11167050B2 (en) 2017-09-26 2021-11-09 National University Corporation Chiba University Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound

Similar Documents

Publication Publication Date Title
JPWO2020145227A5 (https=)
ES2595091T3 (es) Composiciones farmacéuticas con resistencia a CEA soluble
JP2020512281A5 (https=)
TWI780082B (zh) 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
TWI795415B (zh) 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
RU2015116480A (ru) Анти-notch3 антитела и конъюганты антител с лекарственным средством
JPWO2020145228A5 (https=)
AU2016293606A1 (en) Cysteine-substituted immunoglobulins
JPWO2020145228A1 (ja) 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体
WO2003057838A2 (en) Antibodies against the muc18 antigen
JP7812336B2 (ja) 分子連結法または分子工学のためのタンデムリピートがん標的化ペプチドおよびがんセラノスティクスにおけるその使用
WO2023143365A1 (zh) Her3抗体药物偶联物及其用途
WO2023174401A1 (zh) Gpc3抗体药物偶联物及其用途
US20060051359A1 (en) Recombinant immunotoxin and use in treating tumors
Carrasquillo et al. Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72. 3 monoclonal antibody.
ES2278309T3 (es) Anticuerpos que modifican una enfermedad cancerosa.
JP2025524306A (ja) Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体
TW202116353A (zh) 使用酞菁染料靶向分子結合物之治療方法
WO2024097950A1 (en) Radionucleotide and near-infrared dye conjugated antibody for detection of gd2-positive cancer
KR20240099186A (ko) 알파-엽산 수용체에 대한 항체
ES2541907T3 (es) Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos.
JP2009529010A (ja) 癌性疾患修飾抗体
JP2025509338A (ja) Ｒｏｒ１標的結合分子とその使用
TW202607033A (zh) 抗ｒｏｒ２抗體－放射性核種結合物
US20220372125A1 (en) Antigen Specific Binding Domains and Antibody Molecules